Companies › Hinge Bio
1 active drug program in 2 registered trials: 2 Phase 1; Immunology, Other; next expected readout Oct 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| HB2198 Tetravalent bispecific anti-CD19/CD20 antibody with dual Fc domains | CD19, CD20 | Phase 1 | Healthy Volunteer; Systemic Lupus Erthematosus (SLE) | Oct 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07439263 | HB2198 | Phase 1 | Healthy Volunteer | Other | Aug 2026 |
| NCT07491900 | HB2198 | Phase 1 | Systemic Lupus Erthematosus (SLE) | Immunology | Oct 2027 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.